Pfizer Reports Results of Rivipansel in P-III RESET Study for Sickle Cell Disease with Vaso-Occlusive Crisis
Shots:
- The P-III RESET study involves assessing of Rivipansel (IV) vs PBO in 345 patients in a ratio (1:1) with SCD who were hospitalized for a VOC and required treatment with IV opioids aged ≥ 6yrs.
- The P-III RESET (B5201002) study results demonstrated that it did not meet its 1EPs of time to readiness-for-discharge and 2EPs of time-to-discharge- cumulative IV opioid consumption- and time to discontinuation of IV opioids
- Rivipansel is a glycomimetic therapy- acts as a pan-selectin antagonist and binds to E-- P- and L-selectin- being evaluated for VOC in patients with SCD. In 2011- Pfizer signs a WW license agreement with GlycoMimetics to develop & commercialize rivipansel
Click here to read full press release/ article | Ref: Pfizer | Image: Stat
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com